Dr Megan Baldwin is currently Founder, Chief Innovation Officer and Executive Director of Opthea, having led the company as CEO and Managing Director from February 2014 to October 2023. She brings has over 25 years of experience focusing on angiogenesis and therapeutic strategies for cancer and ophthalmic indications.
Dr. Baldwin joined the company in 2008 and has held various positions, including Head of Preclinical R&D and Chief Executive Officer of Opthea Pty Ltd, which at that time, operated as a 100% owned subsidiary of Circadian (now Opthea Ltd), developing OPT-302 for the treatment of wet age-related macular degeneration.
Prior to Opthea, Dr. Baldwin was employed at Genentech (now Roche), the world leader in angiogenesis-based therapies for cancer and other diseases. There she served several years as a researcher for several years, in the group of working with leading angiogenesis expert Napoleone Ferrara, before moving to Genentech’s commercial division where she was responsible for corporate competitive intelligence activities. In these roles, she developed extensive commercial and scientific knowledge in anti-angiogenic and oncology drug development.
Baldwin holds a PhD in Medicine from the University of Melbourne, having conducted her doctoral studies at the Ludwig Institute for Cancer Research. Dr Baldwin is on the board of Ausbiotech and is a member of the Australian Institute for Company Directors.